Leveraging Cell Engineering to Maximize Anti-Tumor Properties of Allogeneic Cells
Time: 12:00 pm
day: Day One - Track A AM
Details:
- Intellia’s differentiated allogeneic platform has shown key characteristics in in vitro assays and in vivo mouse models
- Approach expected to be compatible with standard lymphodepletion
- Allogeneic platform is readily deployable for TCR-T and CAR-T cell therapy
